In just nine months, Sanofi and Regeneron’s Dupixent has come close to reaching another revenue milestone – by the end of the year, the atopic dermatitis treatment will likely be a blockbuster eight times over.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
In the third quarter, Sanofi built on an already successful year, especially when it comes to sales of Dupixent (dupilumab), which is developed in collaboration with Regeneron.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.